



# Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection

Giovanni E. Davogustto, MD; Daniel E. Clark, MD, MPH; Edward Hardison, MD; Ahmad H. Yanis, MD; Brandon D. Lowery, BS; Natasha B. Halasa, MD, MPH; Quinn S. Wells, MD, PharmD, MSCI

## Introduction

A postacute COVID-19 multisystem inflammatory syndrome (MIS) has been recognized as a rare, yet severe, complication of SARS-CoV-2 infection. First characterized in children,<sup>1,2</sup> MIS in adults (MIS-A) has now been reported,<sup>3</sup> leading to the publication of a working case definition by the Centers for Disease Control and Prevention.<sup>4</sup>

The goal of this cohort study was to describe the spectrum of MIS-A presentation after SARS-CoV-2 infection. We identified cases of MIS-A among all adults with laboratory-proven subacute or convalescent SARS-CoV-2 infection at a single tertiary care medical center and described their clinical characteristics and outcomes.

## Methods

This single-center, retrospective cohort study was conducted at Vanderbilt University Medical Center, Nashville, Tennessee. Adults at risk of MIS-A were identified from those hospitalized with positive SARS-CoV-2 test results. The overview of cohort identification and patient selection is described in eFigure 1 in the [Supplement](#). Briefly, we identified all adults 21 years or older with a positive SARS-CoV-2 test result and a subsequent admission from March 1 through September 30, 2020. Those with laboratory-confirmed SARS-CoV-2 infection who were admitted either (1) between 14 and 84 days after positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction test results (RT-PCR) or (2) 15 days before or after positive SARS-CoV-2 serologic test results were classified as being at risk for MIS-A (eFigure 2 in the [Supplement](#)). Patients admitted more than 84 days after positive SARS-CoV-2 RT-PCR test results were excluded. All others were classified as acute COVID-19 admissions for comparison. The study protocol was approved by the Vanderbilt University Medical Center Institutional Review Board. Informed consent was not required as the study met exemption based on 45 CFR §46.104(d) category (4)(iii). This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Demographic characteristics (patients' age, sex, race, and ethnicity) and preexisting chronic comorbid conditions (eMethods and eTable 1 in the [Supplement](#)) captured during clinical encounters were extracted from Vanderbilt University Medical Center Research Derivative<sup>5</sup> and compared between groups. The electronic medical records of individuals at risk for MIS-A were manually reviewed and presented by 1 of 3 authors (G.E.D., D.E.C., or E.H.) and then adjudicated by consensus among the three. Organ system involvement was assessed using previously established criteria (eTable 2 in the [Supplement](#)).<sup>1</sup> Continuous variables were compared using the Mann-Whitney test, and categorical variables were compared with the Fisher exact test. Tests were 2-tailed, and  $P < .05$  was considered significant. Data analyses were performed using R software version 4.0.2 (R Foundation for Statistical Computing).

+ [Invited Commentary](#)

+ [Supplemental content](#)

Author affiliations and article information are listed at the end of this article.

**Open Access.** This is an open access article distributed under the terms of the CC-BY License.

Results

A total of 7196 patients with evidence of SARS-CoV-2 infection by RT-PCR or serologic testing were identified from Vanderbilt University Medical Center electronic health records. Of those, 839 patients (11.7%) were admitted with a positive SARS-CoV-2 test result during the study's time frame. Of those admitted, 156 patients (11.7%) were classified as being at risk for MIS-A, and 683 (81.4%) were classified as having acute COVID-19. After adjudication, 15 of the 156 patients (9.6%) at risk met criteria for MIS-A<sup>4</sup>; the remaining 141 patients (90.3%) were excluded from the analyses.

Among the 698 patients included in this analysis, the median age was 55.8 years (range, 21.2-96.9 years), 372 (53.3%) were men, 326 (46.7%) were women, 406 (58.2%) were White individuals, and 169 (24.2%) were Black individuals. Additional patient characteristics are provided in the **Table**. Patients with MIS-A were younger (median age, 45.1 years; range 21.3-84.0 years vs 56.5 years; range, 21.2-96.9 years for patients admitted for acute COVID-19 symptoms; *P* = .02) and more likely to have evidence of SARS-CoV-2 infection documented by serologic testing (9 patients [60.0%] with MIS-A vs none with COVID-19; *P* < .001). Other demographic characteristics and comorbidities did not differ from those of patients requiring admission for acute SARS-CoV-2 infection.

The clinical characteristics of MIS-A cases are presented in the **Figure, A**. Nine of the 15 patients with MIS-A (60.0%) had acute COVID-19 symptoms, and 3 (20.0%) required admission for acute COVID-19 before being admitted for MIS-A. For patients with prior admission for acute COVID-19, the

**Table. Demographic Characteristics of Patients According to Type of SARS-CoV-2-Related Admission**

Characteristic	Type of admission, No. (%)		P value
	Acute COVID-19 (n = 683)	MIS-A (n = 15)	
Age, median (range), y	56.5 (21.2-96.9)	45.1 (21.3-84.0)	.02
Sex			
Female	321 (47.0)	5 (33.3)	.43
Male	362 (53.0)	10 (66.7)	
Self-reported race			
Asian	18 (2.6)	2 (13.3)	.07
Black	165 (24.2)	4 (26.7)	
White	403 (59.0)	3 (20.0)	
Other or unknown <sup>a</sup>	97 (14.2)	6 (40.0)	
Self-reported ethnicity			
Hispanic	88 (12.9)	2 (13.3)	.95
Non-Hispanic	561 (82.1)	12 (80.0)	
Unknown	34 (5.0)	1 (6.7)	
Underlying comorbid conditions <sup>b</sup>			
Any	522 (76.4)	10 (66.7)	.57
Hypertension	173 (25.3)	3 (20.0)	.86
Coronary artery disease	94 (13.8)	1 (6.7)	.68
Heart failure	55 (8.1)	0	.51
Diabetes mellitus	249 (36.5)	3 (20.0)	.30
Cancer	169 (24.7)	4 (26.7)	>.99
Inflammatory	19 (2.8)	0	>.99
COPD	55 (8.1)	0	.51
Chronic kidney disease	101 (14.8)	3 (20.0)	.85
Obesity (BMI >30)	289 (42.3)	5 (33.3)	.66
No. of comorbid conditions, median (range)	1 (0-8)	1 (0-5)	.22
BMI, median (range)	29.01 (14.4-72.8)	29.2 (20.1-39.2)	.80
Length of admission, median (range),d <sup>c</sup>	5 (0-73)	4 (2-10)	.44
Diagnostic method			
RT-PCR	683 (100)	6 (40.0)	<.001
Serologic testing	0	9 (60.0)	


Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, chronic obstructive pulmonary disease; MIS-A, multisystem inflammatory syndrome in adults; RT-PCR, reverse transcriptase polymerase chain reaction.

<sup>a</sup> Other races were Pacific Islander and Native American.

<sup>b</sup> The listed underlying comorbidities were extracted from the electronic health records using diagnostic and procedure codes specified in eTable 1 in the **Supplement**.

<sup>c</sup> For patients with MIS-A who also had an acute COVID-19 admission, length of admission represents that of MIS-A admission only.

Figure. Clinical Presentation and Organ Involvement of Patients Identified With Multisystem Inflammatory Syndrome in Adults (MIS-A)



A, Data were available for left ventricular ejection fraction (LVEF) from 10 patients, for erythrocyte sedimentation rate (ESR) from 12, for D-dimer level from 9; and for ferritin level from 8. To convert C-reactive protein (CRP) level from milligrams per deciliter to milligrams per liter, multiply by 10. B, Each wedge represents a single patient, and each concentric ring represents an organ system, organized from inside out by frequency of involvement. ICU indicates intensive care unit.

median interval between acute COVID-19 admission and MIS-A admission was 23 days (interquartile range [IQR], 16.0-24.5 days). During MIS-A admission, 5 patients (33.3%) required intensive care treatment for hemodynamic monitoring (n = 3), vasopressor support (n = 1), or noninvasive ventilatory support (n = 1). Furthermore, during MIS-A admission, 3 patients (20.0%) had MIS-A as a clinical diagnosis, 4 (26.7%) received immunosuppressive therapy, 7 (46.6%) received antibiotic therapy, and no participants died. Organ system involvement per patient is shown in the Figure, B. The median number of organ systems involved was 4 (IQR, 2.0-4.5). The gastrointestinal, hematologic, and kidney systems were most commonly affected.

### Discussion

The patients with MIS-A identified in our cohort have a broader distribution of organ involvement and lower illness severity compared with those in previously published series.<sup>4</sup> Most patients who met the MIS-A criteria were not identified as such by the primary clinical team. This study had some limitations. Our data likely underestimate the incidence of MIS-A because many patients with COVID-19-related admissions did not have routine comprehensive clinical and laboratory assessments to screen for this syndrome. These data suggest that, although uncommon, MIS-A has a more heterogeneous clinical presentation than previously appreciated and is commonly underdiagnosed. Future investigations, including prospective enrollments, are necessary to improve the diagnostic and treatment approaches for patients with MIS-A.

## ARTICLE INFORMATION

**Accepted for Publication:** March 24, 2021.

**Published:** May 19, 2021. doi:10.1001/jamanetworkopen.2021.10323

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](#). © 2021 Davogustto GE et al. *JAMA Network Open*.

**Corresponding Author:** Giovanni E. Davogustto, MD, Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Ave, 383 Preston Research Bldg, Nashville, TN 37232-6300 ([giovanni.e.davogustto@vumc.org](mailto:giovanni.e.davogustto@vumc.org)).

**Author Affiliations:** Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (Davogustto, Clark, Wells); Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (Hardison); Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee (Yanis, Halasa); Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee (Lowery); Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (Wells); Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee (Wells).

**Author Contributions:** Dr Davogustto had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Concept and design:* Davogustto, Clark, Hardison, Halasa, Wells.

*Acquisition, analysis, or interpretation of data:* All authors.

*Drafting of the manuscript:* Davogustto, Clark, Hardison.

*Critical revision of the manuscript for important intellectual content:* All authors.

*Statistical analysis:* Davogustto.

*Administrative, technical, or material support:* Davogustto, Clark, Hardison, Yanis, Lowery.

*Supervision:* Wells.

**Conflict of Interest Disclosures:** Dr Halasa reported receiving grants from Sanofi and Quidel outside the submitted work. No other disclosures were reported.

**Funding/Support:** Vanderbilt University's Research Derivative and Research Electronic Data Capture (REDCap) resources are supported by Clinical and Translational Science Award UL1 TRO02243 from the National Center for Advancing Translational Sciences. Research reported in this article was supported in part by award T32HL007411 from the National Heart, Lung, and Blood Institute of the National Institutes of Health (Dr Clark).

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** The content and views expressed in this article are those of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

**Additional Contributions:** We thank Josh F. Peterson, MD, MPH, Lisa Bastarache, MS, and others in the Department of Biomedical Informatics of Vanderbilt University Medical Center (VUMC) for stimulating discussions on the initial design of the study and for creating and making readily available a COVID-19 data registry from electronic health records into VUMC's Research Derivative. We also thank Dan M. Roden, MD (VUMC), for stimulating discussions on study design and his critical review of the manuscript. None of these individuals were compensated for their contributions.

## REFERENCES

1. Feldstein LR, Rose EB, Horwitz SM, et al; Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. *N Engl J Med*. 2020;383(4):334-346. doi:10.1056/NEJMoa2021680
2. Dufort EM, Koumans EH, Chow EJ, et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. *N Engl J Med*. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756
3. Chau VQ, Giustino G, Mahmood K, et al. Cardiogenic shock and hyperinflammatory syndrome in young males with COVID-19. *Circ Heart Fail*. 2020;13(10):e007485. doi:10.1161/CIRCHEARTFAILURE.120.007485
4. Morris SB, Schwartz NG, Patel P, et al. Case Series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection—United Kingdom and United States, March–August 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(40):1450-1456. doi:10.15585/mmwr.mm6940e1

5. Danciu I, Cowan JD, Basford M, et al. Secondary use of clinical data: the Vanderbilt approach. *J Biomed Inform*. 2014;52:28-35. doi:10.1016/j.jbi.2014.02.003

#### SUPPLEMENT.

**eMethods.** Study Design, Participants, and Case Definitions

**eReferences.**

**eTable 1.** Definitions of Chronic Morbidities Extracted From the Electronic Health Record

**eTable 2.** Organ System Involvement Definitions

**eFigure 1.** Overview of Identification of Patients Meeting Multisystem Inflammatory Syndrome in Adults (MIS-A) Case Definition

**eFigure 2.** Identification of Participants at Risk of Multisystem Inflammatory Syndrome in Adults (MIS-A) From the Electronic Health Record